. | Placebo (n = 37) . | Efpeglenatide . | . | ||||
---|---|---|---|---|---|---|---|
. | 0.3 mg (n = 37) . | 1 mg (n = 37) . | 2 mg (n = 33) . | 3 mg (n = 36) . | 4 mg (n = 36) . | Liraglutide 1.8 mg q.d. (n = 36) . | |
Age (years) | 55 ± 9 | 56 ± 11 | 55 ± 9 | 56 ± 10 | 54 ± 10 | 56 ± 10 | 54 ± 11 |
Sex, % | |||||||
Female | 57 | 35 | 49 | 46 | 36 | 50 | 56 |
Male | 43 | 65 | 51 | 55 | 64 | 50 | 44 |
Race, % | |||||||
White | 89 | 84 | 78 | 85 | 78 | 92 | 83 |
Black | 5 | 8 | 16 | 12 | 14 | 6 | 14 |
Asian | 5 | 5 | 5 | 3 | 8 | 3 | 0 |
Diabetes duration (years) | 6.3 ± 5.1 | 7.1 ± 6.2 | 5.1 ± 3.3 | 5.8 ± 5.2 | 5.9 ± 4.8 | 6.1 ± 6.4 | 6.4 ± 4.8 |
Metformin, % | |||||||
Yes | 89 | 92 | 87 | 88 | 92 | 89 | 89 |
No | 11 | 8 | 14 | 12 | 8 | 11 | 11 |
Weight (kg) | 86 ± 18 | 95 ± 20 | 90 ± 18 | 90 ± 17 | 94 ± 19 | 87 ± 18 | 90 ± 16 |
BMI (kg/m2) | 31 ± 5 | 32 ± 5 | 32 ± 5 | 32 ± 4 | 32 ± 5 | 31 ± 6 | 32 ± 4 |
. | Placebo (n = 37) . | Efpeglenatide . | . | ||||
---|---|---|---|---|---|---|---|
. | 0.3 mg (n = 37) . | 1 mg (n = 37) . | 2 mg (n = 33) . | 3 mg (n = 36) . | 4 mg (n = 36) . | Liraglutide 1.8 mg q.d. (n = 36) . | |
Age (years) | 55 ± 9 | 56 ± 11 | 55 ± 9 | 56 ± 10 | 54 ± 10 | 56 ± 10 | 54 ± 11 |
Sex, % | |||||||
Female | 57 | 35 | 49 | 46 | 36 | 50 | 56 |
Male | 43 | 65 | 51 | 55 | 64 | 50 | 44 |
Race, % | |||||||
White | 89 | 84 | 78 | 85 | 78 | 92 | 83 |
Black | 5 | 8 | 16 | 12 | 14 | 6 | 14 |
Asian | 5 | 5 | 5 | 3 | 8 | 3 | 0 |
Diabetes duration (years) | 6.3 ± 5.1 | 7.1 ± 6.2 | 5.1 ± 3.3 | 5.8 ± 5.2 | 5.9 ± 4.8 | 6.1 ± 6.4 | 6.4 ± 4.8 |
Metformin, % | |||||||
Yes | 89 | 92 | 87 | 88 | 92 | 89 | 89 |
No | 11 | 8 | 14 | 12 | 8 | 11 | 11 |
Weight (kg) | 86 ± 18 | 95 ± 20 | 90 ± 18 | 90 ± 17 | 94 ± 19 | 87 ± 18 | 90 ± 16 |
BMI (kg/m2) | 31 ± 5 | 32 ± 5 | 32 ± 5 | 32 ± 4 | 32 ± 5 | 31 ± 6 | 32 ± 4 |
Data are mean ± SD unless otherwise indicated. Percentages may not total 100 because of rounding.